Cancer Trials

BREAST CANCER PROTOCOLS:

CALGB 40101: Cyclophosphamide and Doxorubicin (AC) (4 vs 6 Cycles) vs Paclitaxel (4 vs 6 Cycles) as Adjuvant Therapy for Breast Cancer in Women with 0-3 Positive Axillary Lymph Nodes: A 2 x 2 Factorial Phase III Randomized Study.

PACCT-1: Program for the Assessment of Clinical Cancer Tests: Trial Assigning Individualized Options for Treatment. (TAILOR-X).

SOFT Trial: Phase III Trial Evaluating the Role of Ovarian Function Suppression and the Role of Exemestane as Adjuvant Therapies for Pre-menopausal Women with Endocrine Responsive Breast Cancer.

ACOSOG 21031: Randomized Phase III Trial Comparing 16-18 Weeks of Neoadjuvant Exemestane, Letrozole or Anastrozole in Post-menopausal Women with Stage II/III Estrogen Positive Breast Cancer.

Gi CANCER PROTOCOLS:

BrUOG: ES-103: A Phase I/II Trial of Oxaliplatin, Taxotere, and Capecitabine in Advanced Adenocarcinoma of the Esophagus and Stomach.

CTSU: E 5202: A Randomized Phase III Study Comparing 5-FU, LV and Oxal vs 5-FU, LV, Oxal and Avastin in Patients with Stage II Colon Cancer at High Risk for Recurrence to Determine Prospectively the Prognostic Value of Molecular Makers.

RWH 376-04: Designer T Cells: Phase I Trial of 2nd Generation Anti CEA Designer T Cells in Gastric Cancer.

THORACIC, HEAD & NECK PROTOCOLS:

Abbott M06-880: Open Label, Randomized, Phase 2, Efficacy and Tolerability of ABT-869 in Advanced or Metastatic NSCLS

*RWH 07-349-32: A Phase I Study of Anti-CD3 x Cetuximab-Armed Activated T Cells, Low Dose IL-2, and GM-CSF for EGFR-Positive, Advanced Non-Small Cell Lung Cancer.

MELANOMA PROTOCOL:

Genentech AVF 4096g: Phase II Multi-Center, Randomized DB Trial/Placebo Controlled Trial Evaluating Efficacy and Safety of Bevacizumab in Combination with Carboplatin/Paclitaxel for First Treatment of Patients with Metastatic Melanoma.

PROSTATE CANCER PROTOCOL:

RWH 595-04: Junghans “ Phase Ia/Ib Trial of Anti-PSMA Designer T Cells in Prostate Cancer After Non-Myeloablative Conditioning” (Contact: Robin Davies, RN)

Contact Information
Robin Davies, B.A., B.S.N.,R.N
Director of Oncology Protocol Office
Tel: 401/456-2268 - Fax: 401/456-2658

RWMC CANCER PROTOCOLS

BMT PROTOCOLS:

*RWH 375-07: Phase II Study of Cyclophosphamide, Thiotepa and Carboplatin (CTC) as a Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation in Patients with Lymphoma.

Contact Information
*Patricia Weissman, R.N., B.S.N., M.S.
RWMC Cancer Center Protocol Nurse
Tel: 401/456-2698 - Fax: 401/456-5762

Back to top

Home | About Us | News | Research | Contact Us
Directory | Physician Finder
Patient Care Information | Employment Opportunities
Ways of Giving | Content for Physicians